Blood assessment of the expression levels of matrix metalloproteinase 9 (MMP9) and its natural inhibitor, TIMP1 genes in Iranian schizophrenic patients.
Abstract
Schizophrenia (SCZ) is the most severe chronic mental disorder characterized by abnormal social behavior and disrupted emotions and thought. Like other complex neuropsychological disease, SCZ is caused by a combination of genetic and environmental factors but with a high concordance rate. So far, different genetic factors are revealed to be associated with increased risk of developing SCZ. One of the best ways to investigate the genetic basis of the complex disease is to discover the genetic underlying mechanisms of the defective clinical aspects of the patients. In this regard, genes involved in the developmental mechanisms of the brain such as long-term potentiation (LTP) process that is the basis of synaptic plasticity, memory and learning are considered as strong candidates for SCZ. The aim of the present study was to evaluate the expression levels of two genes that are involved in the LTP regulation in the developing and adult brain, Matrix metallopeptidase9 (MMP9) and TIMP metallopeptidase inhibitor 1 (TIMP1) genes in a blood assessment of schizophrenic patients in comparison to healthy controls by means of quantitative real time PCR. The results of the study showed a significant difference in MMP9/TIPM1 ratio between SCZ patients and healthy controls (P = 0.01). However, no significant difference was detected in the expression level of individual MMP9 and TIMP1 genes in SCZ patients versus healthy controls either in total numbers of subject or in sex based subgroups. Considering the relatively small sample size of the current study, there is a need to replicate this study with further investigations about the mechanism of association of these genes and their functions in the pathogenesis of the SCZ.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Schizophrenia is associated with higher MMP-9/TIMP1 ratios compared to healthy controls.
“Schizophrenia is associated with higher MMP-9/TIMP1 ratios compared to healthy controls (Rahimi et al., 2017).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Rahimi et al., 2017
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369 · see citing works
Diagnostic and Statistical Manual of Mental Disorders(DSM)
Leong, F. T. L. (2008) · Sage eBooks · doi:10.4135/9781412963978.n182 · Cited by 10,858 · see citing works
Structure and function of matrix metalloproteinases and TIMPs
Nagase, H., Visse, R., & MURPHY, G. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.002 · Cited by 3,416 · see citing works
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247 · see citing works
Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9)
den Steen, P. E. V., Dubois, B., Nelissen, I., Rudd, P., Dwek, R., & Opdenakker, G. (2002) · Critical reviews in biochemistry and molecular biology · doi:10.1080/10409230290771546 · Cited by 948 · see citing works
Definition and description of schizophrenia in the DSM-5
Tandon, R., Gäebel, W., Barch, D. M., Bustillo, J., Gur, R. E., Heckers, S., Malaspina, D., Owen, M. J., Schultz, S. K., Tsuang, M. T., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.028 · Cited by 812 · see citing works
Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory
Nagy, V., Bozdagi, O., Matynia, A., Balcerzyk, M., Okulski, P., Dzwonek, J., Costa, R. M., Silva, A. J., Kaczmarek, L., & Huntley, G. W. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4359-05.2006 · Cited by 499 · see citing works
Szklarczyk, A., Lapinska, J., Rylski, M., McKay, R. D. G., & Kaczmarek, L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-03-00920.2002 · Cited by 392 · see citing works
Domenici, E., Willé, D. R., Tozzi, F., Prokopenko, I., Miller, S. L., McKeown, A., Brittain, C. F., Rujescu, D., Giegling, I., Turck, C. W., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009166 · Cited by 347 · see citing works
Important role of matrix metalloproteinase 9 in epileptogenesis
Wilczynski, G. M., Konopacki, F. A., Wilczek, E., Lasiecka, Z., Gorlewicz, A., Michaluk, P., Wawrzyniak, M., Malinowska, M., Okulski, P., Kolodziej, L. R., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200708213 · Cited by 292 · see citing works
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
Hu, W., MacDonald, M. L., Elswick, D. E., & Sweet, R. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12547 · Cited by 286 · see citing works
The Global Prevalence of Schizophrenia
Bhugra, D. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020151 · Cited by 284 · see citing works
Synaptic circuit remodelling by matrix metalloproteinases in health and disease
Huntley, G. W. (2012) · Nature reviews. Neuroscience · doi:10.1038/nrn3320 · Cited by 282 · see citing works
Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease.
Lorenzl, S. (2003) · Neurochemistry International · doi:10.1016/s0197-0186(03)00004-4 · Cited by 243 · see citing works
Metzincin Proteases and Their Inhibitors: Foes or Friends in Nervous System Physiology?
Rivera, S., Khrestchatisky, M., Kaczmarek, L., Rosenberg, G. A., & Jaworski, D. M. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.3467-10.2010 · Cited by 237 · see citing works
Gardner, J., & Ghorpade, A. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10835 · Cited by 199 · see citing works
Lee, J. Y., Kim, H. S., Choi, H. Y., Oh, T. H., & Yune, T. Y. (2012) · Brain · doi:10.1093/brain/aws171 · Cited by 164 · see citing works
TIMP-1 Abolishes MMP-9-Dependent Long-lasting Long-term Potentiation in the Prefrontal Cortex
Okulski, P., Jay, T. M., Jaworski, J., Duniec, K., Dzwonek, J., Konopacki, F. A., Wilczynski, G. M., Sánchez‐Capelo, A., Mallet, J. J., & Kaczmarek, L. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.012 · Cited by 154 · see citing works
Lorenzl, S., Albers, D. S., Narr, S., Chirichigno, J. W., & Beal, M. F. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8019 · Cited by 152 · see citing works
Glutamate signaling in the pathophysiology and therapy of schizophrenia
Lin, C., Lane, H., & Tsai, G. E. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.023 · Cited by 150 · see citing works
MMP-9 deficiency affects axonal outgrowth, migration, and apoptosis in the developing cerebellum
Vaillant, C. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00196-9 · Cited by 135 · see citing works
Kim, Y., Remacle, A. G., Chernov, A. V., Liu, H., Shubayev, I., Lai, C., Dolkas, J., Shiryaev, S. A., Golubkov, V. S., Mizisin, A. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033664 · Cited by 103 · see citing works
Yamamori, H., Hashimoto, R., Ishima, T., Kishi, F., Yasuda, Y., Ohi, K., Fujimoto, M., Umeda-Yano, S., Ito, A., Hashimoto, K., et al. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.09.059 · Cited by 101 · see citing works
Schizophrenia Genetics: Where Next?
Kim, Y., Zerwas, S., Trace, S. E., & Sullivan, P. F. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr031 · Cited by 101 · see citing works
Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction
Michaluk, P., & Kaczmarek, L. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402141 · Cited by 100 · see citing works
Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia: Table 1.
Łepeta, K., & Kaczmarek, L. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv036 · Cited by 75 · see citing works
Cañete-Soler, R., Gui, Y., Linask, K. K., & Muschel, R. J. (1995) · Developmental Brain Research · doi:10.1016/0165-3806(95)00079-s · Cited by 68 · see citing works
Niitsu, T., Ishima, T., Yoshida, T., Hashimoto, T., Matsuzawa, D., Shirayama, Y., Nakazato, M., Shimizu, E., Hashimoto, K., & Iyo, M. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.009 · Cited by 66 · see citing works
Shibasaki, C., Takebayashi, M., Itagaki, K., Abe, H., Kajitani, N., Okada‐Tsuchioka, M., & Yamawaki, S. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw019 · Cited by 56 · see citing works
Noroozi, R., Taheri, M. N., Movafagh, A., Mirfakhraie, R., Solgi, G., Sayad, A., Mazdeh, M., & Darvish, H. (2016) · Autism Research · doi:10.1002/aur.1640 · Cited by 52 · see citing works
Self-citationSchizophrenia genetics complements its mechanistic understanding
Ruzzo, E. K., & Geschwind, D. H. (2016) · Nature Neuroscience · doi:10.1038/nn.4277 · Cited by 20 · see citing works
Up regulation of MMP9 gene expression in female patients with multiple sclerosis
Hamedani, S. Y., Taheri, M. N., Sajjadi, E., Omrani, M. D., Mazdeh, M., Arsang‐Jang, S., Panah, A. S. T., & Sayad, A. (2016) · Human Antibodies · doi:10.3233/hab-160292 · Cited by 19 · see citing works
Self-citationChen, Y., Wu, Y., Mesri, M., & Chen, C. (2016) · Medicine · doi:10.1097/md.0000000000002672 · Cited by 16 · see citing works
Nazdik, M. K., Taheri, M. N., Sajjadi, E., Arsang‐Jang, S., Koohpar, Z. K., Inoko, H., & Sayad, A. (2016) · Human Antibodies · doi:10.3233/hab-160296 · Cited by 16 · see citing works
Self-citationMroczko, B., Koper‐Lenkiewicz, O. M., Groblewska, M., Zboch, M., Kulczyńska‐Przybik, A., Szmitkowski, M., Kornhuber, J., & Lewczuk, P. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.811 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
MMPs in learning and memory and neuropsychiatric disorders
Beroun, A., Mitra, S., Michaluk, P., Pijet, B., Stefaniuk, M., & Kaczmarek, L. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03180-8 · Cited by 207 · see citing works
The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders
Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00270 · Cited by 170 · see citing works
Shibasaki, C., Takebayashi, M., Itagaki, K., Abe, H., Kajitani, N., Okada‐Tsuchioka, M., & Yamawaki, S. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw019 · Cited by 56 · see citing works
Expression Pattern of Long Non-coding RNAs in Schizophrenic Patients
Safari, M. R., Komaki, A., Arsang‐Jang, S., Taheri, M. N., & Ghafouri‐Fard, S. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0640-3 · Cited by 54 · see citing works
Self-citationA conceptualized model linking matrix metalloproteinase-9 to schizophrenia pathogenesis
Bitanihirwe, B. K. Y., & Woo, T.-U. W. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2019.12.015 · Cited by 34 · see citing works
Mohagheghi, M., Eftekharian, M. M., Taheri, M. N., & Alikhani, M. Y. (2017) · Human Antibodies · doi:10.3233/hab-170325 · Cited by 25 · see citing works
Self-citationAzimi, T., Ghafouri‐Fard, S., Omrani, M. D., Mazdeh, M., Arsang‐Jang, S., Sayad, A., & Taheri, M. N. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.10.017 · Cited by 22 · see citing works
Self-citationMetalloproteinases as Biomarkers and Sociomarkers in Human Health and Disease
Costa, D., Scalise, E., Ielapi, N., Bracale, U. M., Andreucci, M., & Serra, R. (2024) · Biomolecules · doi:10.3390/biom14010096 · Cited by 22 · see citing works
Dickerson, F., Vaidya, D., Liu, Y., & Yolken, R. (2023) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2023.02.007 · Cited by 18 · see citing works
Yang, H., Zhang, C., Yang, M. L., Liu, J., Zhang, Y., Liu, D., & Zhang, X. (2024) · BMC Psychiatry · doi:10.1186/s12888-023-05479-0 · Cited by 17 · see citing works
Gregory, M. D., Kippenhan, J. S., Callicott, J. H., Rubinstein, D., Mattay, V. S., Coppola, R., & Berman, K. F. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhy344 · Cited by 13 · see citing works
GRM7 polymorphisms and risk of schizophrenia in Iranian population
Azari, I., Hosseinpour-Moghadam, R., Fallah, H., Noroozi, R., Ghafouri‐Fard, S., & Taheri, M. N. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-018-0380-6 · Cited by 12 · see citing works
Self-citationExpression Analysis of CYFIP1 and CAMKK2 Genes in the Blood of Epileptic and Schizophrenic Patients
Sayad, A., Ranjbaran, F., Ghafouri‐Fard, S., Arsang‐Jang, S., & Taheri, M. N. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1106-2 · Cited by 9 · see citing works
Self-citationKhataee, S., Sadeghi, L., Feizi, M. H., Rashtbari, S., & Marefat, A. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138548 · Cited by 8 · see citing works
Upregulation of vitamin D-related genes in schizophrenic patients
Manjili, F. A., Kalantar, S. M., Arsang‐Jang, S., Ghafouri‐Fard, S., Taheri, M. N., & Sayad, A. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s176301 · Cited by 8 · see citing works
Self-citationDry Eye Disease in Patients With Schizophrenia: A Case-Control Study
Chen, Q., Wei, Z., Wang, L., Xu, X., Wei, Z., Zheng, P., Cao, K., Zhang, Z., Chen, K., & Liang, Q. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.831337 · Cited by 6 · see citing works
Xia, Q.-R., Zhang, C., Liang, J., & Xu, Y. (2019) · International journal of psychiatry in clinical practice · doi:10.1080/13651501.2019.1581895 · Cited by 7 · see citing works
Eftekharian, M. M., Komaki, A., Omrani, M. D., Arsang‐Jang, S., Ganji, M., Taheri, M. N., & Ghafouri‐Fard, S. (2019) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12531 · Cited by 1 · see citing works
Self-citationKosova, M. K., Turgay, F., Yiğittürk, O., Aşıkovalı, S., Kosova, S., Canüzmez, A. E., & Durmaz, B. (2021) · Research Square · doi:10.21203/rs.3.rs-313259/v1
Matrix metalloproteinase 9 gene- MMP9 -DNA methylation status in Turkish schizophrenia patients
Karaaslan, E., Kartalcı, Ş., Bag, H. G., & Acar, C. (2023) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2022-0215
MMP-9 and TIMP-1 Levels in Children and Adolescents with Obsessive Compulsive Disorder
Dalyan, S., Çoban, Ö. G., Erdem, B. K., Yolcu, Ö., Önder, A., Adanır, A. S., Nasıroğlu, S., & Akbaş, S. H. (2023) · Neurochemical Journal · doi:10.1134/s1819712423010038
Jiang, M., Sun, X., Han, Y., Yang, M., Zhang, J., Zhang, X., & Yang, H. (2025) · Research Square · doi:10.21203/rs.3.rs-8288124/v1
Szota, A. M., Ćwiklińska-Jurkowska, M. M., Radajewska, I., Lis, K., Grudzka, P., & Dróżdż, W. (2026) · Biomedicines · doi:10.3390/biomedicines14071535
- Authors
- Rahimi, S., Sayad, A., Moslemi, E., Ghafouri-Fard, S., & Taheri, M.
- Affiliations
- Islamic Azad University, Tehran (IR)
- Shahid Beheshti University (IR)
- Corresponding author
- Sayad, Arezou
- Taheri, Mohammad
- Venue
- Metabolic Brain Disease
- Published
- 2017-06-04
- Volume
- 32
- Issue
- 5
- Pages
- 1537-1542
- ISSN
- 0885-7490 (ISSN-L)
- 1573-7365
- OpenAlex
- W2620760222
- Cited by
- 24
- References
- 35
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 5 · 2017: 2 · 2016: 1
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Metabolic Brain Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- schizophrenia, MMP-9, TIMP-1, long-term potentiation, synaptic plasticity, blood gene expression, genetic susceptibility, Iranian patients
- MeSH terms
- Adult, Aged, Female, Humans, Iran, Male, Middle Aged, Schizophrenia, Schizophrenic Psychology, Gene Expression, Polymerase Chain Reaction, Long-Term Potentiation, DNA, Complementary, Tissue Inhibitor of Metalloproteinase-1, Matrix Metalloproteinase 9
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
